AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker

AstraZeneca is reportedly in discussions regarding a potential acquisition of its United States-based rival, Bristol Myers Squibb. The proposed transaction is valued at approximately $400 billion and would represent one of the largest pharmaceutical mergers in history.

The scale of the potential deal has led to conflicting reports regarding its impact on the industry's competitive landscape. While some initial reporting suggests the merger would result in the creation of the world's largest drugmaker, other analyses indicate the combined entity would rank as the fourth-largest pharmaceutical company globally.